Michael J. Fox - 05 Jun 2024 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Reporting relationship: Director
Issuer ticker: CUE
Reported as of: 05 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Jun 2024, 16:00:08 UTC
Prior SEC filing: 28 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Michael J. Fox by Colin Sandercock, attorney-in-fact

Key filing fact

Michael J. Fox filed Form 4 for Cue Biopharma, Inc. (CUE) on 07 Jun 2024.

Key facts

This page summarizes Michael J. Fox's Form 4 filing for Cue Biopharma, Inc. (CUE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 Jun 2024, 16:00.

Change

Previous filing in this sequence was filed on 28 Mar 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CUE transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +48,800
Change %
Price: $0.000000
Shares after: 48,800
Date: 05 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 48,800
Exercise price: $1.65
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.

Footnote F2

This option was granted on June 5, 2024. The shares underlying the option are scheduled to vest over three years with one-third vesting on the one-year anniversary of the grant date and the balance vesting in eight equal quarterly installments